N,N-二甲基-4-硝基-1-萘胺 | 39139-76-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: N,N-二甲基-4-硝基-1-萘胺
• 英文名称: N,N-dimethyl-4-nitro-α-naphthylamine
• 英文别名: 1-(dimethylamino)-4-nitronaphthalene；1-dimethylamino-4-nitronaphthalene；dimethyl-(4-nitro-[1]naphthyl)-amine；Dimethyl-(4-nitro-[1]naphthyl)-amin；4-Nitro-1-dimethylamino-naphthalin；N.N-Dimethyl-4-nitro-1-naphthylamin；N,N-dimethyl-4-nitronaphthalen-1-amine
• CAS: 39139-76-9
• 化学式: C₁₂H₁₂N₂O₂
• 分子量: 216.239
• InChiKey: JSSWGFLEONKUGN-UHFFFAOYSA-N

物化性质

• 熔点：
  66 °C
• 沸点：
  355.8±30.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  49.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N-二甲基-4-硝基-1-萘胺 在 N-碘代丁二酰亚胺 、 溶剂黄146 作用下， 以62 %的产率得到
  参考文献：
  名称：

  取代N-芳基-1-萘胺类化合物及其制法和药物用途

  摘要：

  本发明属于医药技术领域，公开了一种取代N‑芳基‑1‑萘胺类化合物及其制法和药物用途。具体公开了式(I)化合物所示的取代N‑芳基‑1‑萘胺类化合物，及其生理上可接受的盐，所述化合物的制备方法、药物组合物和在制备尿酸盐转运蛋白1(urate transporter 1,URAT1)抑制剂中的用途，以及在制备预防和/或治疗高尿酸血症、痛风药物中的应用。

  公开号：

  CN116535340A
• 作为产物：
  描述：

  1-氨基-4-硝基萘 、 碘甲烷 在 氢氧化钾 作用下， 以 二甲基亚砜 为溶剂， 反应 3.0h， 以65%的产率得到N,N-二甲基-4-硝基-1-萘胺
  参考文献：
  名称：

  Kurasov, L. A.; Pozharskii, A. F.; Kuz'menko, V. V., Journal of Organic Chemistry USSR (English Translation), 1983, vol. 19, p. 520 - 525

  摘要：

  DOI：

文献信息

• A Simple and Effective Procedure for theN-Permethylation of Amino-Substituted Naphthalenes
  作者：Vladimir I. Sorokin、Valery A. Ozeryanskii、Alexander F. Pozharskii

  DOI：10.1002/ejoc.200390085

  日期：2003.2

  ohols) with good to excellent yields. Steric hindrance does not prevent the reaction. Some amines with electron-withdrawing groups, especially at nonconjugated positions, are also alkylated. The procedure allows the combination of a reduction (catalytic or by tin dichloride in acidic media) and a methylation in a one-pot process. (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)

  多种氨基取代的萘可以通过 Me2SO4/Na2CO3/H2O（醇）系统进行 N-全甲基化，收率非常好。空间位阻不会阻止反应。一些带有吸电子基团的胺，特别是在非共轭位置，也被烷基化。该程序允许在一锅法中将还原（催化或通过酸性介质中的二氯化锡）和甲基化相结合。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)
• Organic nonlinear optical substrates
  申请人：CELANESE CORPORATION

  公开号：EP0214828A2

  公开（公告）日：1987-03-18

  An optically transparent solid solution comprising a homogeneous blend of an organic compound component which exhibits nonlinear optical response, and a thermoplastic polymer component which contains a recurring monomeric unit corresponding to the formula: where R is a substituent selected from hydrogen, methyl and ethyl groups, and R1 is an alkyl substituent containing between about 1-4 carbon atoms.

  一种光学透明固溶体，包含具有非线性光学响应的有机化合物组分与热塑性聚合物组分的均匀混合物，后者含有与式相应的循环单体单元： 其中 R 是选自氢、甲基和乙基的取代基，R1 是含有约 1-4 个碳原子的烷基取代基。
• 10.1021/acs.joc.4c00522
  作者：Tang, Jie、Li, Zhiyou、Meng, Qi、Liu, Long、Huang, Tianzeng、Li, Chunya、Li, Qiang、Chen, Tieqiao

  DOI：10.1021/acs.joc.4c00522

  日期：——

  A CuH-catalyzed reductive coupling of nitroarenes with phosphine oxides is developed, which produces a series of phosphamides in moderate to excellent yields with good functional group tolerance. Gram-scale synthesis and late-stage modification of nitro-aromatic functional molecule niclosamide are also successfully conducted. The mechanism study shows that the nitro group is transformed after being

  开发了一种 CuH 催化的硝基芳烃与氧化膦的还原偶联方法，可以以中等至优异的产率生产一系列磷酰胺，且具有良好的官能团耐受性。硝基芳香族功能分子氯硝柳胺的克级合成及后期修饰也取得成功。机理研究表明，硝基被还原为亚硝基后发生转化，反应过程中涉及亲核加成过程。
• Photosubstitution of 1-methoxy-4-nitronaphthalene with amine nucleophiles: dual pathways
  作者：Nigel J. Bunce、Stephen R. Cater、J. C. Scaiano、Linda J. Johnston

  DOI：10.1021/jo00228a012

  日期：1987.9
• A comparative study between excess-dose users and regular-dose users of rhubarb contained in Kampo medicines
  作者：N. Mantani、T. Kogure、S. Sakai、M. Kainuma、Y. Kasahara、A. Niizawa、Y. Shimada、K. Terasawa

  DOI：10.1078/09447110260571580

  日期：2002.1

  With prolonged use of rhubarb-containing Kampo medicines, some patients come to ask for highdose rhubarb because of deteriorated reactivity to rhubarb. We divided patients into two groups in terms of rhubarb-dose, and compared clinical backgrounds between regular-dose group and excess-dose group. Patients who were treated with rhubarb-containing Kampo extracts (manufactured prescriptions) or Kampo formulae (decoctions) for more than 12 months were enrolled. These two groups were compared for age, sex, shape of stool, abdominal symptoms, existence of hemorrhoids, Kampo diagnosis of abdomen, past stimulant laxative use, duration of stimulant laxative use before the first administration of rhubarb, duration of rhubarb use in our hospital, and initial existence of stimulant pain caused by taking stimulant laxatives for the first time. No significant difference was shown between the two groups in terms of age, duration of stimulant laxative-use before the first prescription of rhubarb, shape of stool, abdominal symptoms, existence of hemorrhoids, or duration of rhubarb-use. However, most patients in the regular-dose group had initial stimulant pain of the abdomen upon taking stimulant laxatives for the first time, but most patients in the excess-dose group did not (p < 0.001). All patients except one in the regular dose group had the sign of "umbilical region tenderness on pressure", but half of the excess-dose group did not have it (P = 0.041). Based on these findings, the absence of "initial stimulant pain" and the absence of "umbilical region tenderness on pressure" may predict increasing or excess use of rhubarb, and long-term use of rhubarb should be discouraged more strongly in the patients without these signs.